Reducing TRIM47 eases heart injury in male-mouse experiments
Experiments in male mice and rat heart cells connect the protein TRIM47 with damage following restored blood flow. Increasing its activity worsened several injury measures; reducing it improved some measures of heart function. The pathway identified in the peer-reviewed experiments involves mitochondrial energy production and fatty-acid use. Human effectiveness and safety of the intervention remain untested.
Science··Morning
Restoring blood flow can add injury
Opening a blocked coronary artery restores oxygen supply, yet the return of circulation can also damage heart muscle. A peer-reviewed experimental study investigated the protein TRIM47 in this reperfusion injury, using male mice and cultured heart cells from newborn rats. Researchers raised or lowered the protein’s production and compared the resulting injury. Increasing TRIM47 worsened the measured damage; reducing it improved several measures, including aspects of heart function after the interruption of blood flow.[1]
A pathway reaches the cell’s power supply
The proposed mechanism begins with EGR1, a regulator of gene activity, increasing TRIM47 production. TRIM47 helps attach a chemical signal to FOXO1, another gene-regulating protein. FOXO1 then moves into the nucleus and inhibits HNF4α, a regulator involved in energy metabolism. Protein-interaction experiments and cellular measurements linked this sequence to disturbed mitochondrial function and fatty-acid oxidation. Mitochondria supply energy needed for contraction, making their activity part of the injury mechanism investigated in the heart cells.[1]
Intervention after injury
The team also delivered a genetic intervention to lower TRIM47 after injury and observed improvements in some measures of cardiac remodelling and function in mice. Human samples from ischemic hearts contained higher protein levels than comparison samples, providing an observational connection to disease. That comparison does not test an intervention in patients. The experiments used male animals, and their findings leave effectiveness, delivery and safety in humans unresolved. The identified pathway remains an experimental candidate for further research.[1]